Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Baghdasaryan, A; Claudel, T; Kosters, A; Gumhold, J; Silbert, D; Thüringer, A; Leski, K; Fickert, P; Karpen, SJ; Trauner, M.
Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation.
Gut. 2010; 59(4):521-530
Doi: 10.1136/gut.2009.186528
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Baghdasaryan Anna
- Trauner Michael
- Co-Autor*innen der Med Uni Graz
- Claudel Thierry
- Fickert Peter
- Leski Katharina
- Silbert-Wagner Dagmar
- Sommer Judith
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Chronic cholangiopathies have limited therapeutic options and represent an important indication for liver transplantation. Curcumin, the yellow pigment of the spice turmeric, has pleiotropic actions and attenuates hepatic damage in animal models of chemically-induced liver injury. Whether curcumin has beneficial effects in cholangiopathies is unknown. Potential anticholestatic, anti-inflammatory and antifibrotic mechanisms of curcumin were explored in vivo in Mdr2(-/-) mice as a murine model of chronic cholangiopathy; as well as in vitro in a cholangiocyte cell line (HuCCT1) and portal myofibroblasts (MFBs) isolated from Mdr2(-/-) mice. Liver damage, cholestasis and fibrosis were reduced in Mdr2(-/-) mice after curcumin feeding. Moreover, curcumin inhibited cholangiocyte proliferation and expression of activation marker vascular cell adhesion molecule-1 in Mdr2(-/-) mice. Curcumin-similar to PPARgamma synthetic agonist troglitazone-directly inhibited TNF-alpha-induced inflammatory activation of cholangiocytes in vitro, whereas these beneficial effects of curcumin were largely blocked by a PPARgamma synthetic antagonist. In addition, curcumin blocked proliferation and activation of portal MFBs by inhibiting ERK1/2 phosphorylation, thus contributing to reduced fibrogenesis. These results show that curcumin may have multiple targets in liver including activation of PPARgamma in cholangiocytes and inhibition of ERK1/2 signalling in MFBs, thereby modulating several central cellular events in a mouse model of cholangiopathy. Targeting these pathways may be a promising therapeutic approach to cholangiopathies.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Anti-Inflammatory Agents, Non-Steroidal - pharmacology Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
- Bile - secretion
- Bile Acids and Salts - biosynthesis
- Bile Ducts - drug effects Bile Ducts - metabolism
- Cell Proliferation - drug effects
- Cells, Cultured -
- Cholangitis, Sclerosing - drug therapy Cholangitis, Sclerosing - metabolism Cholangitis, Sclerosing - pathology
- Curcumin - pharmacology Curcumin - therapeutic use
- Drug Evaluation, Preclinical - methods
- Epithelial Cells - drug effects Epithelial Cells - metabolism
- Fibroblasts - drug effects
- Inflammation Mediators - metabolism
- Liver Cirrhosis, Experimental - drug therapy
- Male -
- Mice -
- Mice, Knockout -
- Mitogen-Activated Protein Kinase 1 - metabolism
- Mitogen-Activated Protein Kinase 3 - metabolism
- P-Glycoproteins - genetics
- PPAR gamma - metabolism
- Signal Transduction - drug effects